PAS
VRTX icon

Park Avenue Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

Park Avenue Securities’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.07M Sell
10,198
-1,713
-14% -$759K 0.03% 384
2026
Q1 		$5.32M Sell
11,911
-1,896
-14% -$884K 0.04% 295
2025
Q4 		$6.26M Sell
13,807
-1,236
-8% -$533K 0.05% 265
2025
Q3 		$5.89M Sell
15,043
-319
-2% -$133K 0.05% 293
2025
Q2 		$6.84M Buy
15,362
+23
+0.1% +$10.6K 0.06% 223
2025
Q1 		$7.44M Buy
15,339
+885
+6% +$412K 0.09% 157
2024
Q4 		$5.82M Buy
14,454
+467
+3% +$216K 0.06% 220
2024
Q3 		$6.5M Sell
13,987
-12
-0.1% -$5.76K 0.07% 181
2024
Q2 		$6.56M Sell
13,999
-240
-2% -$104K 0.08% 174
2024
Q1 		$5.95M Buy
14,239
+1,097
+8% +$464K 0.08% 176
2023
Q4 		$5.35M Buy
13,142
+2,661
+25% +$983K 0.07% 175
2023
Q3 		$3.65M Sell
10,481
-452
-4% -$158K 0.06% 209
2023
Q2 		$3.85M Buy
10,933
+742
+7% +$250K 0.06% 203
2023
Q1 		$3.21M Buy
10,191
+1,513
+17% +$454K 0.06% 206
2022
Q4 		$2.51M Buy
8,678
+863
+11% +$263K 0.04% 246
2022
Q3 		$2.26M Buy
7,815
+105
+1% +$30.2K 0.05% 234
2022
Q2 		$2.17M Sell
7,710
-1,159
-13% -$310K 0.04% 253
2022
Q1 		$2.31M Buy
8,869
+3,041
+52% +$722K 0.04% 251
2021
Q4 		$1.28M Sell
5,828
-1,023
-15% -$199K 0.02% 376
2021
Q3 		$1.24M Sell
6,851
-4,314
-39% -$842K 0.03% 346
2021
Q2 		$2.25M Sell
11,165
-378
-3% -$79.1K 0.05% 208
2021
Q1 		$2.48M Buy
11,543
+4,661
+68% +$1.02M 0.06% 169
2020
Q4 		$1.63M Buy
6,882
+1,959
+40% +$449K 0.05% 189
2020
Q3 		$1.34M Buy
4,923
+790
+19% +$218K 0.04% 183
2020
Q2 		$1.2M Buy
4,133
+245
+6% +$66.4K 0.05% 163
2020
Q1 		$925K Buy
3,888
+436
+13% +$100K 0.08% 86
2019
Q4 		$756K Sell
3,452
-12
-0.3% -$2.43K 0.03% 222
2019
Q3 		$587K Buy
3,464
+121
+4% +$21.4K 0.03% 224
2019
Q2 		$613K Buy
+3,343
New +$584K 0.07% 102

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

Park Avenue Securities's VRTX Position: Q2 2026 in Review

Park Avenue Securities reduced its Vertex Pharmaceuticals (VRTX) stake by 14% in Q2 2026, selling an estimated $759K and leaving 10,198 shares worth $5.07M. The position accounts for 0.03% of the portfolio, ranked #384.

Park Avenue Securities first reported a position in VRTX in Q2 2019 and has held it in 29 quarters since. The position peaked at $7.44M in Q1 2025. 305 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Park Avenue Securities held 10,198 shares of Vertex Pharmaceuticals worth $5.07M as of Q2 2026.
  • Park Avenue Securities sold 1,713 Vertex Pharmaceuticals shares in Q2 2026, an estimated $759K.
  • Vertex Pharmaceuticals made up 0.03% of Park Avenue Securities's portfolio in Q2 2026, its #384 holding.
  • Park Avenue Securities first reported a position in Vertex Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Park Avenue Securities's Vertex Pharmaceuticals position peaked at $7.44M in Q1 2025.
  • 305 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.